CBL0137 (CBL) targets FACT (facilitates chromatin transcription), a histone chaperone that is expressed at high levels in tumours and is required for the expression of transcription factors that are essential for TIC maintenance.6,7 Recently, we reported that CBL as a single agent preferentially targets TICs in SCLC and has potent anti-cancer activity against SCLCs when combined with cisplatin.8 Here, CBL is linked to neoplasm.